Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CXCR3 | P49682 | 5/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.41 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.41 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26265633 | 1.00 | CA1 (0.45) | CA1CA2CXCR3AKT1GAA | |
| SCHEMBL22536411 | 0.92 | TLR2 (0.45) | CA1CA2CXCR3AKT1GAA | |
| SCHEMBL23921370 | 0.90 | SIRT5 (0.44) | CXCR3AKT1SIRT5 | |
| SCHEMBL23790802 | 0.88 | AKT1 (0.42) | AKT1GAACTSSCTSKALDH1A1 | |
| SCHEMBL23921371 | 0.86 | BCHE (0.39) | CA1CA2CXCR3AKT1SIRT5 | |
| SCHEMBL25719625 | 0.86 | GAA (0.58) | CA1CA2GAAALDH1A1 | |
| SCHEMBL21792191 | 0.84 | ALDH1A1 (0.47) | CXCR3GAACTSKSIRT5KLK7 | |
| SCHEMBL19543629 | 0.82 | CTSS (0.53) | CA1CA2CXCR3GAACTSS | |
| SCHEMBL8752938 | 0.80 | TPSAB1 (0.51) | CA1CA2GAA | |
| SCHEMBL23921368 | 0.80 | KLK7 (0.42) | CXCR3GAASIRT5KLK7KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220033518-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATES | AMBRX,INC. (US) | 2022-02-03 | — | — | US | disclosed |
| US-10954270-B2 | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | AMBRX, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3470413-A2 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | Ambrx, Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| US-10208123-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-9796754-B2 | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | AMBRX, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20150152190-A1 | Prostate-Specific Membrane Antigen Antibody Drug Conjugates | AMBRX, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150152190-A1 | Prostate-Specific Membrane Antigen Antibody Drug Conjugates | AMBRX, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150141624-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141624-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| WO-2012166560-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | AMBRX, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141624-A1 | Anti-CD70 Antibody Drug Conjugates | CD74, CD63, CD47 | CA1 3116/4885CA2 3077/4885CXCR3 912/4885 |
| US-10208123-B2 | Anti-CD70 antibody drug conjugates | CD74, CD63, CD47 | CA1 3116/4885CA2 3077/4885CXCR3 912/4885 |
| US-10954270-B2 | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | DDOST, DAD1, PTMS | CA1 2978/4885CA2 1437/4885CXCR3 3395/4885 |
| US-20220033518-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATES | KLK3, PTMS, DDOST | CA1 827/4885CA2 606/4885CXCR3 2733/4885 |
| US-20150152190-A1 | Prostate-Specific Membrane Antigen Antibody Drug Conjugates | KLK3, PTMS, DDOST | CA1 827/4885CA2 606/4885CXCR3 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.